News | March 25, 2026
Siemens Healthineers expands radiotherapy beyond cancer, targets osteoarthritis pain
The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge
It promises fewer injections for vision loss patients
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
Subscribe To Our Newsletter & Stay Updated
